Navigation Links
YM BioSciences Closes Public Offering of Common Shares
Date:12/17/2010

r of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and an
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 The global ... billion by 2020, according to a new study by ... the rising demand for effective vaccines and drugs in ... unmet medical needs is expected to drive market demand ... to enhance agricultural productivity via the use of genetically ...
(Date:7/28/2014)... , July 28, 2014 Research and Markets ... Size Analysis Market 2014-2018" report to their offering. ... size analysis is a technique used to determine the size ... liquid. It is crucial to analyze the size of particles ... particle size analysis is performed to determine the behavior and ...
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... study by researchers from the University of Leicester ... function, unlocking the potential to create new materials ... has been published in the prestigious academic journal ... laser technique to examine in rich detail the ... cluster containing an acetylene molecule and a single ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. ... contract research organization (CRO) that provides design, development, ... registries to many of the world,s leading pharmaceutical ... for the Second Annual Vaccine Industry Excellence Award ...
... service revenue of $264.5 million grows 7.8% year-over-year- ... of $0.25- Net quarterly book-to-bill ratio equates to ... PRXL ) today announced its financial ... 2009.For the three months ended March 31, 2009, ...
... Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC ... has secured rights to seven key patents from Company ... patents that will significantly enhance Sinobiopharma,s ability to execute ... to market.The patents are for the following:, ...
Cached Biology Technology:Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/28/2014)... fertility problems, many of these due to genetic factors. ... such genes, which reduce an individual,s ability to reproduce, ... Institute of Science that recently appeared in Nature ... only can it explain the high rates of male ... the causes of genetic diseases and their treatment. ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
Breaking Biology News(10 mins):Mutations from Venus, mutations from Mars 2Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... Might those bacteria lead oil companies to change their methods ... same time reducing the carbon dioxide that burning oil and ... be possible. Larter, professor of geoscience and holder ... University of Calgary, was the keynote speaker today for the ...
... a firm link between environmental change and human disease ... a team of scientists from the University of Wisconsin-Madison, ... of the CDC journal Emerging Infectious Diseases, ... incidence of malaria to land-use practices in the Amazon. ...
... bacteria in seven species of sharks and redfish captured ... of these wild, free-swimming fish harbored several drug-resistant bacterial ... Journal of Zoo and Wildlife Medicine , found antibiotic-resistant ... also found multidrug-resistant bacteria in fish at nearly all ...
Cached Biology News:Incidence of malaria jumps when Amazon forests are cut 2Incidence of malaria jumps when Amazon forests are cut 3Wild sharks, redfish harbor antibiotic-resistant bacteria 2
... gene gun optimization kit provides a variety ... affecting particle delivery with the Helios gene ... of 0.6 micrometer, 1.0 micrometer, and 1.6 ... cartridge kit, that provides 0.5 g polyvinylpyrrolidone ...
... Expression (SAGE) is a powerful genome-wide ... cost-effective outsourcing solution for sequencing of ... SAGE sequencing service provides our clients ... Phred20 read lengths (40 SAGE tags ...
... sequencing is the experimental process of determining ... The automated DNA Sequencing is based on ... polymerase, which allows cycle sequencing reactions. The ... in a capillary instrument controlled by a ...
... calibration, and validation (MCV) plate ... used for hands-free startup, shutdown, ... the Bio-Plex suspension array system. ... use with Bio-Plex Manager software ...
Biology Products: